• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by BioPlus Acquisition Corp.

    10/16/23 4:15:07 PM ET
    $BIOS
    Blank Checks
    Finance
    Get the next $BIOS alert in real time by email
    15-12G 1 ea186747-1512g_bioplus.htm FORM 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-41116

     

    BioPlus Acquisition Corp.

    (Exact name of registrant as specified in its charter)

     

    260 Madison Avenue

    Suite 800

    New York, New York 10026

    (212) 287-4092

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant

    Class A Ordinary Shares, par value $0.0001 per share

    Warrants, each exercisable for one Class A Ordinary Share for $11.50 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) ☒  
    Rule 12g-4(a)(2) ☐  
    Rule 12h-3(b)(1)(i) ☒  
    Rule 12h-3(b)(1)(ii) ☐  
    Rule 15d-6 ☐  
    Rule 15-22(b) ☐  

     

    Approximate number of holders of record as of the certification or notice date: 1

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, BioPlus Acquisition Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Dated: October 16, 2023

     

      BIOPLUS ACQUISITION CORP.
       
      By: /s/ Ross Haghighat
      Name:  Ross Haghighat
      Title: Chief Executive Officer and
    Chief Financial Officer

     

     

     

     

     

    Get the next $BIOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

    New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa

    10/4/23 7:30:00 AM ET
    $BIOS
    Blank Checks
    Finance

    Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

    EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co

    10/4/23 7:30:00 AM ET
    $BIOS
    Blank Checks
    Finance

    Carbonhand is available for Veterans in the US

    Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function. KISTA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle, Trivet Medical's mission is to develop underrepresented and underserved healthcare conditions through

    8/29/23 3:03:00 AM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    SEC Filings

    View All

    SEC Form 15-12G filed by BioPlus Acquisition Corp.

    15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)

    10/16/23 4:15:07 PM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form 25-NSE filed by BioPlus Acquisition Corp.

    25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)

    10/6/23 4:03:10 PM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form RW filed by BioPlus Acquisition Corp.

    RW - BioPlus Acquisition Corp. (0001856653) (Filer)

    10/4/23 7:39:57 AM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bioplus Sponsor Llc

    4 - BioPlus Acquisition Corp. (0001856653) (Issuer)

    6/12/23 9:17:36 PM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    Financials

    Live finance-specific insights

    View All

    Purple Innovation Announces Cooperative Framework with Coliseum Capital

    Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o

    4/13/23 4:05:00 PM ET
    $ADES
    $BIOS
    $LAZY
    Major Chemicals
    Industrials
    Blank Checks
    Finance

    $BIOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

    2/12/24 4:14:06 PM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

    2/9/24 10:26:34 AM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

    2/7/24 2:00:23 PM ET
    $BIOS
    Blank Checks
    Finance